• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

经典嗜铬细胞瘤原始描述中MEN-2的证据。

Evidence of MEN-2 in the original description of classic pheochromocytoma.

作者信息

Neumann Hartmut P H, Vortmeyer Alexander, Schmidt Dieter, Werner Martin, Erlic Zoran, Cascon Alberto, Bausch Birke, Januszewicz Andrzej, Eng Charis

机构信息

Department of Nephrology, University of Freiburg Medical Center, Freiburg im Breisgau, Germany.

出版信息

N Engl J Med. 2007 Sep 27;357(13):1311-5. doi: 10.1056/NEJMoa071407.

DOI:10.1056/NEJMoa071407
PMID:17898100
Abstract

The first description of pheochromocytoma in 1886 has been attributed to Felix Fränkel, who described an 18-year-old woman with bilateral adrenal "sarcoma and angio-sarcoma." We reviewed the publication and then approached and assessed relatives of the patient to update the findings with the use of current technology. In-depth review revealed that the histopathological findings were consistent with pheochromocytoma. Because the proband was young and had bilateral disease at diagnosis, we hypothesized that she had an inherited condition. The presence of germ-line RET mutations in four living relatives demonstrates that the original patient and her family had multiple endocrine neoplasia type 2 and provides molecular evidence that she had pheochromocytoma.

摘要

1886年对嗜铬细胞瘤的首次描述归功于费利克斯·弗兰克尔,他描述了一名18岁患有双侧肾上腺“肉瘤和血管肉瘤”的女性。我们查阅了该出版物,然后联系并评估了患者的亲属,以利用当前技术更新研究结果。深入审查发现,组织病理学结果与嗜铬细胞瘤一致。由于先证者诊断时年轻且患有双侧疾病,我们推测她患有遗传性疾病。四名在世亲属中存在种系RET突变,这表明最初的患者及其家族患有2型多发性内分泌肿瘤,并提供了她患有嗜铬细胞瘤的分子证据。

相似文献

1
Evidence of MEN-2 in the original description of classic pheochromocytoma.经典嗜铬细胞瘤原始描述中MEN-2的证据。
N Engl J Med. 2007 Sep 27;357(13):1311-5. doi: 10.1056/NEJMoa071407.
2
Multiple endocrine neoplasia 2A due to a unique C609S RET mutation presents with pheochromocytoma and reduced penetrance of medullary thyroid carcinoma.由于独特的C609S RET突变导致的多发性内分泌腺瘤病2A型表现为嗜铬细胞瘤和甲状腺髓样癌的低外显率。
Clin Endocrinol (Oxf). 2005 Dec;63(6):676-82. doi: 10.1111/j.1365-2265.2005.02400.x.
3
Asymptomatic bilateral adrenal pheochromocytoma in a patient with a germline V804M mutation in the RET proto-oncogene.一名RET原癌基因存在种系V804M突变的患者出现无症状双侧肾上腺嗜铬细胞瘤。
Clin Endocrinol (Oxf). 2007 Jul;67(1):29-33. doi: 10.1111/j.1365-2265.2007.02830.x. Epub 2007 Apr 27.
4
[C634R mutation of the protooncongene RET and molecular diagnosis in multiple endocrine neoplasia type 2 in a large Moroccan family].[原癌基因RET的C634R突变与摩洛哥一个大家族中2型多发性内分泌肿瘤的分子诊断]
Bull Cancer. 2008 Apr;95(4):457-63. doi: 10.1684/bdc.2008.0621.
5
Coexistence of MEN 2A and papillary thyroid carcinoma and a recurrent pheochromocytoma 23 years after surgery: report of a case and a review of the Japanese literature.MEN 2A与甲状腺乳头状癌并存及术后23年复发性嗜铬细胞瘤:1例报告并文献复习
Jpn J Clin Oncol. 1995 Aug;25(4):153-8.
6
[Analysis of mutations in the RET proto-oncogene in patients with medullary thyroid tumor].[甲状腺髓样肿瘤患者RET原癌基因突变分析]
Genetika. 2003 Jun;39(6):847-54.
7
Age-related neoplastic risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germ line RET Cys634Trp (TGC>TGG) mutation.由种系RET Cys634Trp(TGC>TGG)突变引起的2A型多发性内分泌肿瘤的年龄相关肿瘤风险概况及外显率估计
Endocr Relat Cancer. 2008 Dec;15(4):1035-41. doi: 10.1677/ERC-08-0105. Epub 2008 Sep 15.
8
Multiple endocrine neoplasia type 2 and the RET protooncogene: from bedside to bench to bedside.2型多发性内分泌腺瘤与RET原癌基因:从床边到实验室再回到床边
Mol Cell Endocrinol. 2006 Mar 9;247(1-2):34-40. doi: 10.1016/j.mce.2005.10.028. Epub 2005 Dec 15.
9
A large family with hereditary MTC: role of RET genetic analysis in differential diagnosis between MEN 2A and FMTC.一个患有遗传性甲状腺髓样癌的大家族:RET基因分析在2A型多发性内分泌腺瘤病与家族性甲状腺髓样癌鉴别诊断中的作用
Horm Metab Res. 2001 Jan;33(1):52-6. doi: 10.1055/s-2001-12627.
10
Experience of prophylactic thyroidectomy in multiple endocrine neoplasia type 2A kindreds with RET codon 804 mutations.2A 型多发性内分泌腺瘤病家系中 RET 密码子 804 突变患者预防性甲状腺切除术的经验。
Clin Endocrinol (Oxf). 2005 Dec;63(6):636-41. doi: 10.1111/j.1365-2265.2005.02394.x.

引用本文的文献

1
Pheochromocytoma in MEN2.多发性内分泌腺瘤病2型中的嗜铬细胞瘤
Recent Results Cancer Res. 2025;223:211-235. doi: 10.1007/978-3-031-80396-3_8.
2
[30 years of prophylactic thyroidectomy for hereditary medullary thyroid cancer : A milestone in translational medicine].遗传性甲状腺髓样癌预防性甲状腺切除术30年:转化医学的一个里程碑
Chirurgie (Heidelb). 2024 Aug;95(8):638-650. doi: 10.1007/s00104-024-02105-x. Epub 2024 May 28.
3
Minimally Invasive Management of Hemorrhagic Pheochromocytoma-A Rare Case Report.嗜铬细胞瘤出血的微创治疗——1例罕见病例报告
Surg J (N Y). 2023 Mar 26;9(1):e52-e57. doi: 10.1055/s-0043-1762554. eCollection 2023 Jan.
4
Pheochromocytoma-induced Subarachnoid and Intracerebral Hemorrhage.嗜铬细胞瘤诱发的蛛网膜下腔出血和脑出血
J Endocr Soc. 2022 Nov 16;7(1):bvac176. doi: 10.1210/jendso/bvac176. eCollection 2022 Nov 17.
5
A Comprehensive Analysis Identified the Key Differentially Expressed Circular Ribonucleic Acids and Methylation-Related Function in Pheochromocytomas and Paragangliomas.一项综合分析确定了嗜铬细胞瘤和副神经节瘤中关键的差异表达环状核糖核酸及其甲基化相关功能。
Front Genet. 2020 Feb 25;11:15. doi: 10.3389/fgene.2020.00015. eCollection 2020.
6
Catecholamine-induced cardiomyopathy in a patient with pheochromocytoma and polycystic kidney and liver disease: a case report.嗜铬细胞瘤合并多囊肾和肝病患者的儿茶酚胺诱导性心肌病:一例报告
Eur Heart J Case Rep. 2019 Jun 1;3(2). doi: 10.1093/ehjcr/ytz062.
7
Precision Surgery for Pheochromocytomas and Paragangliomas.精准外科手术治疗嗜铬细胞瘤和副神经节瘤
Horm Metab Res. 2019 Jul;51(7):470-482. doi: 10.1055/a-0926-3618. Epub 2019 Jul 15.
8
Multiple Endocrine Neoplasia Syndromes from Genetic and Epigenetic Perspectives.从遗传和表观遗传学角度看多发性内分泌肿瘤综合征
Biomark Insights. 2018 Jul 2;13:1177271918785129. doi: 10.1177/1177271918785129. eCollection 2018.
9
Max Schottelius: Pioneer in Pheochromocytoma.马克斯·肖特利乌斯:嗜铬细胞瘤研究先驱。
J Endocr Soc. 2017 Jul 1;1(7):957-964. doi: 10.1210/js.2017-00208.
10
Advances in the management of MEN2: from improved surgical and medical treatment to novel kinase inhibitors.MEN2 管理的进展:从改进的手术和药物治疗到新型激酶抑制剂。
Endocr Relat Cancer. 2018 Feb;25(2):T1-T13. doi: 10.1530/ERC-17-0325. Epub 2017 Nov 15.